Blau Farmacêutica (BLAU3) Q4 2024 earnings summary

Executive summary

• Achieved record net revenue of BRL 1.75 billion in 2024, up 28% year-over-year, with strong performance in both hospital and retail segments and 22% organic growth.

• Recurring net income increased 23% to BRL 220 million, despite negative exchange rate impacts and higher financial expenses.

• Strategic investments in biotechnology, R&D, and capacity expansion support long-term growth and global ambitions, including the acquisition of Bergamo and a new subsidiary in Mexico.

• Financial position strengthened with significant net debt reduction (down 85% to BRL 24 million) and increased financial flexibility.

• Comprehensive income totaled BRL 224.8 million, reflecting positive foreign currency translation adjustments.

Financial highlights

• Net revenue reached BRL 1.75 billion in 2024, up 28% year-over-year; 4Q24 net revenue was BRL 456 million, up 18%.

• Gross margin improved to 37.5% in 2024 (+900 bps); gross profit was BRL 659 million, up 34% from 2023.

• Recurring EBITDA margin rose to 22.3% in 2024 (+340 bps), with recurring EBITDA at BRL 391 million (+51%).

• Recurring net income was BRL 220 million in 2024 (+23%).

• Free cash flow to firm surged to BRL 276 million, 23x higher than 2023.

Outlook and guidance

• Focus on launching new products, expanding market share, and global expansion, including the launch of Blau Mexicana in 2025.

• Continued investments in R&D, capacity, and verticalization of strategic products, with management expecting further growth in both institutional and retail channels.